Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
SRDX Surmodics Inc
- Stocks
- Healthcare
- NASDAQ: SRDX
Price (delayed)
$27.21
Market cap
$389.08M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.4
Enterprise value
$389.53M
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. Surmodics
Highlights
SRDX's quick ratio is up by 10% year-on-year but it is down by 6% since the previous quarter
The net income has declined by 38% since the previous quarter
The company's EPS fell by 37% QoQ
Key stats
What are the main financial stats of SRDX
Market
Valuations
Earnings
Shares outstanding
14.3M
Market cap
$389.08M
Enterprise value
$389.53M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.53
Price to sales (P/S)
3.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.2
Revenue
$121.58M
Gross profit
$89.2M
Operating income
-$12.47M
Net income
-$19.86M
EBIT
-$11.07M
EBITDA
-$1.76M
Free cash flow
-$7.44M
Per share
Balance sheet
Liquidity
EPS
-$1.4
EPS diluted
-$1.4
Free cash flow per share
-$0.52
Book value per share
$7.71
Revenue per share
$8.51
TBVPS
$6.9
Total assets
$163.21M
Total liabilities
$52.97M
Debt
$29.63M
Equity
$110.25M
Working capital
$57.8M
Debt to equity
0.27
Current ratio
5.14
Quick ratio
3.06
Net debt/EBITDA
-0.25
Margins
Efficiency
Dividend
EBITDA margin
-1.4%
Gross margin
73.4%
Net margin
-16.3%
Operating margin
-10.3%
Return on assets
-11.6%
Return on equity
-17.3%
Return on invested capital
-12.7%
Return on capital employed
-7.4%
Return on sales
-9.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SRDX stock price
How has the Surmodics stock price performed over time
Intraday
0.2%
1 week
-2.33%
1 month
-0.55%
1 year
-13.87%
YTD
-31.29%
QTD
-10.87%
Financial performance
How have Surmodics's revenue and profit performed over time
Revenue
$121.58M
Gross profit
$89.2M
Operating income
-$12.47M
Net income
-$19.86M
Gross margin
73.4%
Net margin
-16.3%
SRDX's operating margin has dropped by 176% year-on-year and by 66% since the previous quarter
The operating income has plunged by 165% YoY and by 60% from the previous quarter
The net margin has declined by 42% since the previous quarter
The net income has declined by 38% since the previous quarter
Price vs fundamentals
How does SRDX's price correlate with its fundamentals
Growth
What is Surmodics's growth rate over time
Valuation
What is Surmodics stock price valuation
P/E
N/A
P/B
3.53
P/S
3.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.2
The company's EPS fell by 37% QoQ
The stock's price to book (P/B) is 25% less than its last 4 quarters average of 4.7 and 20% less than its 5-year quarterly average of 4.4
Surmodics's equity has decreased by 11% YoY
SRDX's P/S is 36% below its 5-year quarterly average of 5.0 and 26% below its last 4 quarters average of 4.3
SRDX's revenue is down by 15% YoY and by 3.1% QoQ
Efficiency
How efficient is Surmodics business performance
The company's return on sales has shrunk by 162% YoY and by 86% QoQ
The ROIC has plunged by 152% YoY and by 81% from the previous quarter
The ROE has contracted by 42% from the previous quarter
SRDX's return on assets is down by 41% since the previous quarter
Dividends
What is SRDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SRDX.
Financial health
How did Surmodics financials performed over time
The current ratio has grown by 17% YoY but it has contracted by 6% from the previous quarter
The total assets has contracted by 11% YoY
The debt is 73% smaller than the equity
The debt to equity has grown by 13% YoY and by 3.8% from the previous quarter
Surmodics's equity has decreased by 11% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.